0.00Open0.00Pre Close0 Volume0 Open Interest36.00Strike Price0.00Turnover0.00%IV29.61%PremiumNov 8, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma231.46Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pfizer Stock Discussion
1. Consumer Staples: Companies that produce essential goods, such as food, beverages, household products, and personal care items, tend to be more stable because demand for these products remains consistent regardless of the poli...
dipping
continues
According to the Securities Times APP, on November 5, the official website of the National Medical Products Administration (NMPA) showed that Pfizer's talazoparib tosylate capsules (talazoparib) have been approved for marketing. Talazoparib was originally developed by BioMarin, acquired by Medivation from BioMarin in 2015, and Pfizer acquired Medivation for $14 billion in 2016, thus talazoparib belongs to Pfizer since then.
10M in volume with over 5B free float.. This will always be a shorts paradise.. Too many outstanding shares for such a cheap stock!🤢🤮
wow... talk about a sh*show with this stock!
🤢🤮
in terms of risk vs earnings
$15 - $20 range should be fair value range
margin of safety $10 - $15
XLV is downtrending
No comment yet